Announcements Trials
Browse Landscape

Status

Completed 7Active not recruiting 1

Sponsor Class

INDUSTRY 8OTHER 3

Study Type

Observational 8Interventional 2

Sponsor

Cancer Type

Classical hematology 7

Conditions

Venous Thromboembolism 4Treatment of Venous Thromboembolism in Cancer Patients 3Neoplasms 3Venous Thrombosis 1Pulmonary Embolism 1Embolism 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Rivaroxaban × Clear all
NCT04618913 2026-05-26

VICTORIE

Pfizer

Active not recruiting
1 enrolled
Classical hematology

Embolism, Neoplasms, Venous Thromboembolism

NCT04979780 2024-10-31

OSCAR-US

Bayer

Completed
3,708 enrolled
Classical hematology

Treatment of Venous Thromboembolism in Cancer Patients

NCT05150938 2023-12-18

A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)

Bayer

Completed
5,737 enrolled
Classical hematology

Treatment of Venous Thromboembolism in Cancer Patients

NCT02742623 2023-11-07

COSIMO

Bayer

Completed
528 enrolled

Neoplasms, Pulmonary Embolism, Venous Thrombosis

NCT05112666 2023-04-03

A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

Bayer

Completed
2,601 enrolled
Classical hematology

Treatment of Venous Thromboembolism in Cancer Patients

NCT05461807 2022-10-26

H2H-OSCAR-US

Bayer

Completed
2,437 enrolled
Classical hematology

Neoplasms, Venous Thromboembolism

NCT03965741 2021-11-30

PRACTISE

Bayer

Completed
97,765 enrolled
Classical hematology

Venous Thromboembolism

NCT03214172 2018-09-06

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Bayer

Completed
1,000 enrolled
Classical hematology

Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡